Higher risk due to health condition

Booster doses are efficient at mounting strong T-cell immune responses in people living with HIV

In a peer-reviewed paper published in Viruses, a CITF-funded  study led by Dr Mohammad-Ali Jenabian (Université du Québec à Montréal, UQAM), along with Dr. Aslam Anis (University of British Columbia) found that a third dose of COVID-19 vaccines induced robust cellular immune responses in people living with HIV that are comparable to what is observed in individuals without HIV.

2023-02-28T15:41:01-05:00February 28, 2023|Higher risk due to health condition|

Vaccine effectiveness in people with chronic kidney disease can be reliably estimated using various study designs

A CITF-funded study conducted by Dr. Matthew Oliver (University of Toronto) and his team revealed that estimates of vaccine effectiveness (VE) in individuals diagnosed with chronic kidney disease are consistent across three common study designs: test-negative, pseudo-test-negative, and cohort studies.

2023-02-06T15:32:49-05:00February 6, 2023|Higher risk due to health condition|

COVID-19 vaccine immunogenicity in people with HIV

A CITF-funded study, published in AIDS and led by Drs. Cecilia Costiniuk (McGill University) and Aslam Anis (University of British Columbia, found that vaccine-induced antibodies to SARS-CoV-2 were elicited in over 90% of people living with HIV (PLWS). Of those, most (92%), maintained those antibodies for six months following a second dose, although this percentage is less than it was for HIV-negative controls.

2023-01-17T14:33:40-05:00January 17, 2023|Higher risk due to health condition|

Kidney transplant recipients do not produce as robust an antibody response to COVID-19 vaccines as otherwise healthy individuals

CITF-funded research from Drs. Matthew Oliver and Michelle Hladunewich (University of Toronto), now published in Transplantation Direct, found that over 50% of kidney transplant recipients (KTRs) lacked Omicron-specific neutralizing antibodies one month following a third vaccine dose. Antibody levels in those that developed the Omicron-specific antibodies were well preserved at 3 months.

2023-01-09T12:30:37-05:00January 9, 2023|Higher risk due to health condition|

Vaccine-induced immune responses are as durable in people living with HIV as in people without HIV

A CITF-funded study published in AIDS, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV.

2023-01-09T12:05:19-05:00January 9, 2023|Higher risk due to health condition|

Vaccine-induced immune responses are as durable in people living with HIV as in people without HIV

A CITF-funded study, published in preprint, and not yet peer-reviewed, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV. 

2022-11-07T14:52:02-05:00November 7, 2022|Higher risk due to health condition|

Antibody responses to the first four doses of SARS-CoV-2 vaccine in patients with IBD

A CITF-funded study published in The Lancet Gastroenterology & Hepatology by Drs. Gilaad Kaplan (University of Calgary) and Sasha Bernatsky (McGill University) on behalf of the STOP COVID-19 in IBD Research Group, showed a robust antibody response was achieved in individuals with IBD after the fourth dose of COVID-19 vaccine, similar in magnitude to that which followed the third dose.

2022-11-07T14:39:18-05:00November 7, 2022|Higher risk due to health condition|

A third dose of COVID-19 vaccine yields greater protection in allogeneic stem cell transplant recipients

A CITF-funded study, published in Transplant Cell Therapy, from Dr. Deepali Kumar’s team (University of Toronto) shows that a third dose of COVID-19 vaccine resulted in stronger humoral and cell-mediated immunity in allogeneic stem cell transplant (Allo-SCT) recipients, when compared to the initial two-dose vaccine regimen.

2022-10-24T15:44:32-04:00October 24, 2022|Higher risk due to health condition|
Go to Top